SSI Diagnostica acquires the American company CTK Biotech
SSI Diagnostica acquires the American company CTK Biotech, which developed one of the worlds most...
Rapid AST with
MIC & SIR direct from PBC
Full Expert System on board
with dynamic algorithm
Easy to use interface
with low hands-on time
Continuous loading for optimal handling of urgent care patients
Incorporationg international guidelines & recommendations: EUCAST, CLSI & CA-SFM
LIS BI-directional with easy Bacteria
An overall combined CA for both GNs and GPs of 96.3%. The presented time to report data obtained by QMAC-dRASTTM in this study being of 3-8 hours for blood-culture specimens examined strongly support a further possible improvement in the workflow for handling blood stream infections.
Reporting based on MALDI-TOF MS results on susceptible/resistant pathogens, optimal targeted treatment was found respectively in 79%/63%, unnecessary broad-spectrum treatment in 16%/5%, suboptimal treatment in 4%/1%, and appropriate antibiotic treatment 100%/68%. Adding QMAC-dRAST results to the decision making raised the percentage of optimal antibiotic treatments to 98.2%
By eliminating requirement for sub-cultures, dRAST™ improves your lab efficiency by reducing TAT for Antibiotic Susceptibility testing
dRAST™ system does not require turbidity measurements